恒瑞医药：海曲泊帕乙醇胺片获受理

Core Viewpoint - Heng Rui Medicine has received the acceptance notice from the National Medical Products Administration for its drug application of Haequbopamine Ethanolamine Tablets, indicating progress in the approval process for a new treatment for immune thrombocytopenic purpura (ITP) [1] Group 1 - The drug application is specifically for adult patients and children aged 6 years and older who have had poor responses to previous treatments such as corticosteroids and immunoglobulins [1]